Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Afatinib in Pediatric Recurrent/Refractory Solid Tumors
NCT02372006Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Apr 2015
- Primary completion
- Aug 2020
- Modality
- Small Molecules
- Countries
- 12
01
Overview
A Phase 2 trial of afatinib in neuroectodermal tumor, rhabdomyosarcoma (RMS), solid tumor, sponsored by Boehringer Ingelheim. Started Apr 2015; status: completed.
02
Drugs
afatinib
03
Conditions
neuroectodermal tumorrhabdomyosarcoma (RMS)solid tumor
Beyond the preview
Go deeper on NCT02372006.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02372006.